Journal article · 2018 · Open access
109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis
CNS Spectrums, 23(1), 70–71 · Published 1 February 2018 · DOI 10.1017/s1092852918000093
In brief
“109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis” is a 2018 journal article by Celso Arango and 5 co-authors, published in CNS Spectrums. OpenAlex counts 2 citations as of 20 November 2026. It is open access: the full text is free to read at CNS Spectrums.
- Citations
- 2
- Most cited in
- 2021 (1)
- Field-weighted impact
- 0.16
- Authors
- 6
Abstract
Study Objective This analysis assessed the relative efficacy and tolerability of lurasidone versus other atypical antipsychotics in the treatment of pediatricschizophrenia. Methods A systematic literature review identified 13 randomized-controlled trials for the treatment of pediatric schizophrenia. A Bayesian network meta-analysis compared the efficacy and tolerability of the following atypical antipsychotics: aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, andziprasidone. Patients were 7-17 years old and trial duration ranged from 6-12 weeks. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause treatment discontinuation, and extrapyramidal symptoms. Results from the fixed effect models were reported as mean differences for continuous outcomes and odds ratios for binary outcomes; each with a 95% credible interval. Results Lurasidone had significantly greater improvement compared with placebo for PANSS (-7.95 [-11.76, -4.16]) and CGI-S (-0.44 [-0.67, -0.22]), but did not differ from comparators. The differences in weight gain for lurasidone relative to comparators were as follows: clozapine (-3.81kg [-8.03, 0.42]), olanzapine (-3.62kg [-4.84, -2.41]), quetiapine (-2.13kg [-3.20, -1.08]), risperidone (-1.16kg [-2.14, -0.17]), asenapine (-0.98kg [-1.71, -0.24]), paliperidone (-0.85kg [-1.57, -0.14]), aripiprazole (-0.15kg [-0.88, 0.58]), and ziprasidone (0.38kg [-0.49, 1.24]); all were statistically significant except for clozapine, aripiprazole, and ziprasidone. Rates of all-cause discontinuation andextrapyramidal symptoms were similar for lurasidone and comparators, except aripiprazole and paliperidone, which had higher rates of all-cause discontinuation. Conclusions In this network meta-analysis of atypical antipsychotics for the treatment of adolescent schizophrenia, lurasidone was associated with similar efficacy, but less weight gain than active comparators. Funding Acknowledgements This study was funded by Sunovion Pharmaceuticals Inc.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., Rajagopalan, K., & Loebel, A. D. (2018). 109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis. CNS Spectrums, 23(1), 70–71. https://doi.org/10.1017/s1092852918000093
MLA 9
Arango, Celso, et al. “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis.” CNS Spectrums, vol. 23, no. 1, 2018, pp. 70–71. https://doi.org/10.1017/s1092852918000093.
Chicago
Arango, Celso, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Krithika Rajagopalan, and Antony D Loebel. 2018. “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis.” CNS Spectrums 23 (1): 70–71. https://doi.org/10.1017/s1092852918000093.
Harvard
Arango, C. et al. (2018) ‘109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis’, CNS Spectrums, 23(1), pp. 70–71. doi:10.1017/s1092852918000093.
IEEE
C. Arango, D. Ng‐Mak, E. Finn, A. Byrne, K. Rajagopalan, and A. D. Loebel, “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis,” CNS Spectrums, vol. 23, no. 1, pp. 70–71, 2018, doi: 10.1017/s1092852918000093.
BibTeX
@article{arango2018comparative,
title = {{109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis}},
author = {Arango, Celso and Ng‐Mak, Daisy and Finn, Elaine and Byrne, Aidan and Rajagopalan, Krithika and Loebel, Antony D},
journal = {CNS Spectrums},
year = {2018},
volume = {23},
number = {1},
pages = {70--71},
doi = {10.1017/s1092852918000093},
url = {https://doi.org/10.1017/s1092852918000093}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- lurasidone
- pediatric schizophrenia
- atypical antipsychotics
- drug efficacy comparison
- tolerability
- weight gain
- extrapyramidal symptoms
- treatment discontinuation
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., Rajagopalan, K., & Loebel, A. D. (2018). 109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis. CNS Spectrums, 23(1), 70–71. https://doi.org/10.1017/s1092852918000093
How many times has this paper been cited?
2 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at CNS Spectrums: sign in and open the PDF from this page.
Who wrote this paper?
Celso Arango, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Krithika Rajagopalan, Antony D Loebel.
What is the DOI of this paper?
10.1017/s1092852918000093, permanently at https://doi.org/10.1017/s1092852918000093. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.